We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 0.10% | 997.80 | 997.60 | 998.00 | 1,000.50 | 981.20 | 994.60 | 5,800,566 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 33.14 | 8.71B |
By Matteo Castia
Smith & Nephew PLC on Thursday resumed its full-year guidance following a revenue increase in the first quarter, thanks to a return to growth across most divisions.
The medical-technology group said first-quarter revenue rose 12% year-on-year, or 6.2% on an underlying basis, to $1.26 billion.
Smith & Nephew said reported growth included benefits of 3.4% from foreign-exchange effects and 1.9% from acquisitions.
Meanwhile, all three global franchises of the FTSE 100 company returned to growth on a reported and underlying basis, it said.
Smith & Nephew said it is now targeting full-year underlying revenue growth in the range of 10% to 13%, assuming improvement in conditions through the year.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
April 29, 2021 02:52 ET (06:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Smith & Nephew Chart |
1 Month Smith & Nephew Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions